CN103180314A - 抑制白三烯产生的*二唑类抑制剂 - Google Patents
抑制白三烯产生的*二唑类抑制剂 Download PDFInfo
- Publication number
- CN103180314A CN103180314A CN2011800500399A CN201180050039A CN103180314A CN 103180314 A CN103180314 A CN 103180314A CN 2011800500399 A CN2011800500399 A CN 2011800500399A CN 201180050039 A CN201180050039 A CN 201180050039A CN 103180314 A CN103180314 A CN 103180314A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- optionally substituted
- mmol
- pharmaceutically acceptable
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(*)(c1n[o]c(*)n1)c1ccc(*)cc1* Chemical compound *C(*)(c1n[o]c(*)n1)c1ccc(*)cc1* 0.000 description 10
- QQUURFREBSVNMH-UHFFFAOYSA-N Nc(nc1)nc(OCc2ccccc2)c1Br Chemical compound Nc(nc1)nc(OCc2ccccc2)c1Br QQUURFREBSVNMH-UHFFFAOYSA-N 0.000 description 2
- WZQOVZJEWJVWIZ-UHFFFAOYSA-N CC(C)(C(C)(C)O1)OB1S1OC(C)(C)C(C)(C)O1 Chemical compound CC(C)(C(C)(C)O1)OB1S1OC(C)(C)C(C)(C)O1 WZQOVZJEWJVWIZ-UHFFFAOYSA-N 0.000 description 1
- NQIQVSBZIWZCNH-UHFFFAOYSA-N CC(C)(CNc1ncc(-c2nc(C(C)(C3CC3)c(cc3)ccc3-c3cnc(N)nc3)n[o]2)nc1)O Chemical compound CC(C)(CNc1ncc(-c2nc(C(C)(C3CC3)c(cc3)ccc3-c3cnc(N)nc3)n[o]2)nc1)O NQIQVSBZIWZCNH-UHFFFAOYSA-N 0.000 description 1
- GMBZJYLKAKVMOK-UHFFFAOYSA-N CC(C)C(C)(C(/N=C(/c1cnccc1)\O)=N)c(cc1)ccc1Br Chemical compound CC(C)C(C)(C(/N=C(/c1cnccc1)\O)=N)c(cc1)ccc1Br GMBZJYLKAKVMOK-UHFFFAOYSA-N 0.000 description 1
- NPHRIJCNKWNIPM-UHFFFAOYSA-N CC(C)C(C)(c1n[o]c(-c2cccnc2)n1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1 Chemical compound CC(C)C(C)(c1n[o]c(-c2cccnc2)n1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1 NPHRIJCNKWNIPM-UHFFFAOYSA-N 0.000 description 1
- ZJQAKBVJJMKLEX-UHFFFAOYSA-N CC(C)Nc(nc1)ncc1Br Chemical compound CC(C)Nc(nc1)ncc1Br ZJQAKBVJJMKLEX-UHFFFAOYSA-N 0.000 description 1
- KQCAPJKLNQUTAS-UHFFFAOYSA-N CC(C1CC1)(/C(/N)=N/O)c(cc1)ccc1Br Chemical compound CC(C1CC1)(/C(/N)=N/O)c(cc1)ccc1Br KQCAPJKLNQUTAS-UHFFFAOYSA-N 0.000 description 1
- YHYUUMHDHPRGBB-UHFFFAOYSA-N CC(C1CC1)(C(N)=N)c(cc1)ccc1-c1cnc(N)nc1 Chemical compound CC(C1CC1)(C(N)=N)c(cc1)ccc1-c1cnc(N)nc1 YHYUUMHDHPRGBB-UHFFFAOYSA-N 0.000 description 1
- OHKXCIAFRSRETF-UHFFFAOYSA-N CC(C1CC1)(c1n[o]c(-c(nc2)cnc2-[n]2cncc2)n1)c(cc1)ccc1-c1cnc(N)nc1 Chemical compound CC(C1CC1)(c1n[o]c(-c(nc2)cnc2-[n]2cncc2)n1)c(cc1)ccc1-c1cnc(N)nc1 OHKXCIAFRSRETF-UHFFFAOYSA-N 0.000 description 1
- XCLFNHPRXDSCEK-BYSADCEQSA-N CCC(C)(/C=C\C)/C=N\C(\N)=C(\CO)/C=C Chemical compound CCC(C)(/C=C\C)/C=N\C(\N)=C(\CO)/C=C XCLFNHPRXDSCEK-BYSADCEQSA-N 0.000 description 1
- NWUSLHRUTRPNJS-UHFFFAOYSA-N CCc1n[o]c(-c2cnccc2)n1 Chemical compound CCc1n[o]c(-c2cnccc2)n1 NWUSLHRUTRPNJS-UHFFFAOYSA-N 0.000 description 1
- KEGOKBSLUSAYSD-HKBQPEDESA-N C[C@](C1CC1)(c1n[o]c(-c2c[n](CC(N(C)C)=O)nc2)n1)c(cc1)ccc1-c(cnc(N)n1)c1OCc1ccccc1 Chemical compound C[C@](C1CC1)(c1n[o]c(-c2c[n](CC(N(C)C)=O)nc2)n1)c(cc1)ccc1-c(cnc(N)n1)c1OCc1ccccc1 KEGOKBSLUSAYSD-HKBQPEDESA-N 0.000 description 1
- HDHCQGBSPRROAH-AREMUKBSSA-N C[C@](C1CC1)(c1n[o]c(-c2c[n](CC(N(C)C)=O)nc2)n1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1 Chemical compound C[C@](C1CC1)(c1n[o]c(-c2c[n](CC(N(C)C)=O)nc2)n1)c1ccc(B2OC(C)(C)C(C)(C)O2)cc1 HDHCQGBSPRROAH-AREMUKBSSA-N 0.000 description 1
- CTWZYPZCDJKBRS-UHFFFAOYSA-N Fc(nc1)ncc1Br Chemical compound Fc(nc1)ncc1Br CTWZYPZCDJKBRS-UHFFFAOYSA-N 0.000 description 1
- HIVQAWXDBPYNDU-UHFFFAOYSA-N Nc(nc1)c(CO)cc1Br Chemical compound Nc(nc1)c(CO)cc1Br HIVQAWXDBPYNDU-UHFFFAOYSA-N 0.000 description 1
- ZNHIZVRENCRAPA-UHFFFAOYSA-N Nc(nc1)nc(Cl)c1Br Chemical compound Nc(nc1)nc(Cl)c1Br ZNHIZVRENCRAPA-UHFFFAOYSA-N 0.000 description 1
- FXJOTWLLDJYKAG-UHFFFAOYSA-N OC(c(nc1)cnc1Cl)=O Chemical compound OC(c(nc1)cnc1Cl)=O FXJOTWLLDJYKAG-UHFFFAOYSA-N 0.000 description 1
- IMBBXSASDSZJSX-UHFFFAOYSA-N OC(c1c[nH]nc1)=O Chemical compound OC(c1c[nH]nc1)=O IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37392510P | 2010-08-16 | 2010-08-16 | |
| US61/373,925 | 2010-08-16 | ||
| US201161492176P | 2011-06-01 | 2011-06-01 | |
| US61/492,176 | 2011-06-01 | ||
| PCT/US2011/047356 WO2012024150A1 (en) | 2010-08-16 | 2011-08-11 | Oxadiazole inhibitors of leukotriene production |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103180314A true CN103180314A (zh) | 2013-06-26 |
Family
ID=44511591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800500399A Pending CN103180314A (zh) | 2010-08-16 | 2011-08-11 | 抑制白三烯产生的*二唑类抑制剂 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8658661B2 (enExample) |
| EP (1) | EP2606045B1 (enExample) |
| JP (1) | JP5619284B2 (enExample) |
| KR (1) | KR20130100105A (enExample) |
| CN (1) | CN103180314A (enExample) |
| AP (1) | AP2013006678A0 (enExample) |
| AR (1) | AR082696A1 (enExample) |
| AU (1) | AU2011292285A1 (enExample) |
| BR (1) | BR112013003439A2 (enExample) |
| CA (1) | CA2807364A1 (enExample) |
| CL (1) | CL2013000455A1 (enExample) |
| CO (1) | CO6680645A2 (enExample) |
| EA (1) | EA201300250A1 (enExample) |
| EC (1) | ECSP13012494A (enExample) |
| MX (1) | MX2013001872A (enExample) |
| NZ (1) | NZ605690A (enExample) |
| PE (1) | PE20130751A1 (enExample) |
| PH (1) | PH12013500301A1 (enExample) |
| SG (1) | SG187549A1 (enExample) |
| TW (1) | TW201238947A (enExample) |
| UY (1) | UY33557A (enExample) |
| WO (1) | WO2012024150A1 (enExample) |
| ZA (1) | ZA201300238B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807364A1 (en) | 2010-08-16 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EP2609092B1 (en) * | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| IN2013DN02555A (enExample) * | 2010-09-23 | 2015-08-07 | Boehringer Ingelheim Int | |
| US8580825B2 (en) * | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| US9073895B2 (en) * | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| EP2686291B1 (en) | 2011-03-18 | 2016-11-30 | Boehringer Ingelheim International GmbH | Process for preparing carboxylic acids |
| US9174980B2 (en) * | 2012-01-31 | 2015-11-03 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| AR089853A1 (es) * | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| WO2013119751A1 (en) * | 2012-02-09 | 2013-08-15 | Boehringer Ingelheim International Gmbh | Process for preparing carboxamidine compounds |
| WO2014095381A1 (en) | 2012-12-19 | 2014-06-26 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| WO2014095249A1 (en) | 2012-12-19 | 2014-06-26 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| EP2746256A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| EP2746277A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| EP2746279A1 (en) | 2012-12-19 | 2014-06-25 | Basf Se | Fungicidal imidazolyl and triazolyl compounds |
| CN103724279B (zh) * | 2014-01-20 | 2016-04-06 | 新发药业有限公司 | 一步成环制备2-甲基-4-氨基-5-氨基甲基嘧啶的便捷合成方法 |
| US10562869B2 (en) | 2014-03-17 | 2020-02-18 | Remynd Nv | Oxadiazole compounds |
| IL291418B2 (en) | 2022-03-16 | 2024-05-01 | Anima Biotech Inc | Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment |
| JP2023140319A (ja) | 2022-03-22 | 2023-10-04 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05112564A (ja) * | 1991-04-30 | 1993-05-07 | Otsuka Pharmaceut Factory Inc | フエニルチアゾール誘導体 |
| CN101039938A (zh) * | 2004-10-18 | 2007-09-19 | 默克公司 | 作为flap抑制剂的二苯基取代的烷烃 |
| WO2007130499A2 (en) * | 2006-05-01 | 2007-11-15 | Virobay, Inc. | Antiviral agents |
| WO2008030369A1 (en) * | 2006-09-01 | 2008-03-13 | Merck & Co., Inc. | Inhibitors of 5 -lipoxygenase activating protein ( flap) |
| CN101282976A (zh) * | 2005-08-10 | 2008-10-08 | 史密丝克莱恩比彻姆公司 | 作为选择性hm74a激动剂的黄嘌呤衍生物 |
| CN101687791A (zh) * | 2007-05-04 | 2010-03-31 | 阿米拉制药公司 | 5-脂氧化酶-活化蛋白（flap）抑制剂 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141019A (en) * | 1964-07-14 | Chaohj | ||
| NL132134C (enExample) * | 1963-03-22 | |||
| BR9811678A (pt) * | 1997-07-10 | 2000-09-19 | Janssen Pharmaceutica Nv | Derivados de 6-azauracila de inibição de il-5 |
| EP0987265A1 (en) * | 1998-09-18 | 2000-03-22 | Janssen Pharmaceutica N.V. | Interleukin-5 inhibiting 6-azauracil derivatives |
| ES2260031T3 (es) | 1999-08-06 | 2006-11-01 | Janssen Pharmaceutica N.V. | Derivados de 6-azauracilo que inhiben la interleucina-5. |
| US7319108B2 (en) | 2004-01-25 | 2008-01-15 | Sanofi-Aventis Deutschland Gmbh | Aryl-substituted heterocycles, process for their preparation and their use as medicaments |
| WO2007017262A1 (en) * | 2005-08-10 | 2007-02-15 | Smithkline Beecham Corporation | Xanthine derivatives as selective hm74a agonists |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| WO2007120574A2 (en) | 2006-04-11 | 2007-10-25 | Merck & Co., Inc. | Diaryl substituted alkanes |
| EP2452683A3 (en) * | 2006-06-26 | 2012-08-22 | Amgen Inc. | Methods for treating atherosclerosis |
| FR2906866A1 (fr) * | 2006-10-10 | 2008-04-11 | Felix Ifrah | Luminaire comprenant au moins un moyen d'eclairage dont l'activation s'effectue par l'emission d'un rayonnement lumineux |
| WO2008050200A1 (en) * | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
| EP2148878A4 (en) | 2007-04-20 | 2011-08-10 | Merck Canada Inc | NEW HETEROAROMATIC COMPOUNDS AS INHIBITORS OF STEAROYL-COENZYME-A-DELTA-9-DESATURASE |
| US20100190761A1 (en) | 2007-06-20 | 2010-07-29 | Anthony Ogawa | Diphenyl substituted alkanes |
| CA2702225A1 (en) | 2007-10-10 | 2009-04-16 | Merck Sharp & Dohme Corp. | Diphenyl substituted cycloalkanes |
| TW201040175A (en) * | 2009-02-04 | 2010-11-16 | Pfizer | 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6H)-one derivatives |
| WO2011143466A1 (en) | 2010-05-12 | 2011-11-17 | Vanderbilt University | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| CA2807364A1 (en) | 2010-08-16 | 2012-02-23 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
| EP2609092B1 (en) | 2010-08-26 | 2015-04-01 | Boehringer Ingelheim International GmbH | Oxadiazole inhibitors of leukotriene production |
| US8580825B2 (en) | 2010-09-23 | 2013-11-12 | Boehringer Ingelheim International Gmbh | Oxadiazole inhibitors of leukotriene production |
-
2011
- 2011-08-11 CA CA2807364A patent/CA2807364A1/en not_active Abandoned
- 2011-08-11 WO PCT/US2011/047356 patent/WO2012024150A1/en not_active Ceased
- 2011-08-11 SG SG2013003694A patent/SG187549A1/en unknown
- 2011-08-11 EP EP11748842.9A patent/EP2606045B1/en active Active
- 2011-08-11 JP JP2013524874A patent/JP5619284B2/ja active Active
- 2011-08-11 PH PH1/2013/500301A patent/PH12013500301A1/en unknown
- 2011-08-11 NZ NZ605690A patent/NZ605690A/en not_active IP Right Cessation
- 2011-08-11 PE PE2013000279A patent/PE20130751A1/es not_active Application Discontinuation
- 2011-08-11 AP AP2013006678A patent/AP2013006678A0/xx unknown
- 2011-08-11 BR BR112013003439A patent/BR112013003439A2/pt not_active IP Right Cessation
- 2011-08-11 MX MX2013001872A patent/MX2013001872A/es not_active Application Discontinuation
- 2011-08-11 KR KR1020137003938A patent/KR20130100105A/ko not_active Withdrawn
- 2011-08-11 CN CN2011800500399A patent/CN103180314A/zh active Pending
- 2011-08-11 EA EA201300250A patent/EA201300250A1/ru unknown
- 2011-08-11 AU AU2011292285A patent/AU2011292285A1/en not_active Abandoned
- 2011-08-12 US US13/208,582 patent/US8658661B2/en active Active
- 2011-08-15 TW TW100129127A patent/TW201238947A/zh unknown
- 2011-08-15 AR ARP110102966A patent/AR082696A1/es unknown
- 2011-08-15 UY UY0001033557A patent/UY33557A/es not_active Application Discontinuation
-
2013
- 2013-01-10 ZA ZA2013/00238A patent/ZA201300238B/en unknown
- 2013-02-14 CL CL2013000455A patent/CL2013000455A1/es unknown
- 2013-02-15 CO CO13031460A patent/CO6680645A2/es not_active Application Discontinuation
- 2013-03-15 EC ECSP13012494 patent/ECSP13012494A/es unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05112564A (ja) * | 1991-04-30 | 1993-05-07 | Otsuka Pharmaceut Factory Inc | フエニルチアゾール誘導体 |
| CN101039938A (zh) * | 2004-10-18 | 2007-09-19 | 默克公司 | 作为flap抑制剂的二苯基取代的烷烃 |
| CN101282976A (zh) * | 2005-08-10 | 2008-10-08 | 史密丝克莱恩比彻姆公司 | 作为选择性hm74a激动剂的黄嘌呤衍生物 |
| WO2007130499A2 (en) * | 2006-05-01 | 2007-11-15 | Virobay, Inc. | Antiviral agents |
| WO2008030369A1 (en) * | 2006-09-01 | 2008-03-13 | Merck & Co., Inc. | Inhibitors of 5 -lipoxygenase activating protein ( flap) |
| CN101687791A (zh) * | 2007-05-04 | 2010-03-31 | 阿米拉制药公司 | 5-脂氧化酶-活化蛋白（flap）抑制剂 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013003439A2 (pt) | 2019-09-24 |
| ZA201300238B (en) | 2014-06-25 |
| US8658661B2 (en) | 2014-02-25 |
| PH12013500301A1 (en) | 2013-03-25 |
| CL2013000455A1 (es) | 2013-05-03 |
| JP5619284B2 (ja) | 2014-11-05 |
| AP2013006678A0 (en) | 2013-01-31 |
| TW201238947A (en) | 2012-10-01 |
| CA2807364A1 (en) | 2012-02-23 |
| EP2606045B1 (en) | 2016-01-06 |
| US20120220561A1 (en) | 2012-08-30 |
| CO6680645A2 (es) | 2013-05-31 |
| EA201300250A1 (ru) | 2013-08-30 |
| ECSP13012494A (es) | 2013-04-30 |
| NZ605690A (en) | 2014-06-27 |
| WO2012024150A1 (en) | 2012-02-23 |
| MX2013001872A (es) | 2013-09-02 |
| KR20130100105A (ko) | 2013-09-09 |
| SG187549A1 (en) | 2013-03-28 |
| AU2011292285A1 (en) | 2013-01-31 |
| JP2013534245A (ja) | 2013-09-02 |
| PE20130751A1 (es) | 2013-06-21 |
| UY33557A (es) | 2012-03-30 |
| EP2606045A1 (en) | 2013-06-26 |
| AR082696A1 (es) | 2012-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5619284B2 (ja) | ロイコトリエン産生のオキサジアゾール阻害薬 | |
| JP5690839B2 (ja) | ロイコトリエン産生のベンゾイミダゾール阻害薬 | |
| JP5862669B2 (ja) | ロイコトリエン産生のオキサジアゾール阻害剤 | |
| JP6069771B2 (ja) | ロイコトリエン生成の阻害薬としてのフェニル−ｃ−オキサジアゾール誘導体併用療法 | |
| CN104583208A (zh) | 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物 | |
| KR20200081436A (ko) | 파르네소이드 x 수용체 조정제로서의 알켄 화합물 | |
| KR102732405B1 (ko) | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 | |
| US8580825B2 (en) | Oxadiazole inhibitors of leukotriene production | |
| EP3704107A1 (en) | Multicyclic compounds as farnesoid x receptor modulators | |
| JP5713511B2 (ja) | ロイコトリエン産生のオキサジアゾール阻害剤 | |
| WO2012055888A1 (en) | Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists | |
| US11273146B2 (en) | Benzofuran derivatives and their use as bromodomain inhibitors | |
| MX2007016541A (es) | Compuestos quimicos. | |
| HK1182389A (en) | Oxadiazole inhibitors of leukotriene production | |
| HK40078531B (zh) | 杂芳基化合物 | |
| HK1183300A (en) | Oxadiazole inhibitors of leukotriene production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1182389 Country of ref document: HK |
|
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130626 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1182389 Country of ref document: HK |